Success Metrics

Clinical Success Rate
86.2%

Based on 50 completed trials

Completion Rate
86%(50/58)
Active Trials
7(9%)
Results Posted
46%(23 trials)
Terminated
8(11%)

Phase Distribution

Ph phase_4
18
24%
Ph phase_2
13
17%
Ph not_applicable
14
19%
Ph phase_1
14
19%
Ph early_phase_1
2
3%
Ph phase_3
11
15%

Phase Distribution

16

Early Stage

13

Mid Stage

29

Late Stage

Phase Distribution72 total trials
Early Phase 1First-in-human
2(2.8%)
Phase 1Safety & dosage
14(19.4%)
Phase 2Efficacy & side effects
13(18.1%)
Phase 3Large-scale testing
11(15.3%)
Phase 4Post-market surveillance
18(25.0%)
N/ANon-phased studies
14(19.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

50 of 61 finished

Non-Completion Rate

18.0%

11 ended early

Currently Active

7

trials recruiting

Total Trials

75

all time

Status Distribution
Active(8)
Completed(50)
Terminated(11)
Other(6)

Detailed Status

Completed50
Terminated8
unknown6
Active, not recruiting4
Recruiting3
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
75
Active
7
Success Rate
86.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (2.8%)
Phase 114 (19.4%)
Phase 213 (18.1%)
Phase 311 (15.3%)
Phase 418 (25.0%)
N/A14 (19.4%)

Trials by Status

completed5067%
not_yet_recruiting11%
recruiting34%
terminated811%
unknown68%
withdrawn34%
active_not_recruiting45%

Recent Activity

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more
NCT05662228Phase 2

Therapies for Down Syndrome Regression Disorder

Active Not Recruiting
NCT01949662Phase 2

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Active Not Recruiting
NCT03743649Phase 2

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Active Not Recruiting
NCT06004115Phase 4

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Recruiting
NCT07179978

Lorazepam and the Risk of Serious Adverse Events

Completed
NCT00696033Not Applicable

Exploring the Effects of Diazepam and Lorazepam

Completed
NCT06799494Phase 4

HPV Vaccine Reduced Dose

Recruiting
NCT04923659Early Phase 1

Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity

Active Not Recruiting
NCT03905798

LORA-PITA IV General Investigation

Completed
NCT03030417Phase 1

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Completed
NCT05599126Phase 4

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems

Recruiting
NCT06370442Phase 3

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

Not Yet Recruiting
NCT04715230Phase 2

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Terminated
NCT01441843Phase 4

Resistance Under the Microscope

Completed
NCT01810458

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

Completed
NCT00109395Phase 2

Lorazepam Sedation for Critically Ill Children

Completed
NCT03435692Not Applicable

Post Operative Pain Control After Pediatric Hip Surgery

Terminated
NCT03090620Phase 4

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Completed
NCT00881556Early Phase 1

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terminated
NCT00624780Phase 4

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
75